FeesSafety
Pluang+

Tempus AI reports 23% revenue growth and $193M in new data deals over 5 years

Company Fundamentals
19 Nov 2026, 08:35 WIB
The Motley Fool
View Source
Bullish
Tempus AI reports 23% revenue growth and $193M in new data deals over 5 years

Tempus AI announced a 23% year-over-year revenue increase to $411.5 million in Q3 2026, driven by rising test prices and long-term biopharma data licensing agreements expected to generate $193 million over five years. Regulatory approvals will boost oncology test pricing, adding $80 million in average selling price in 2027. The company achieved positive adjusted EBITDA of $25.6 million, reflecting operational scale and profitability. Tempus plans to reinvest in technology and data to maintain its leadership in oncology diagnostics and sustain long-term growth.

Tempus AI holds a market cap of $11.57 billion and an enterprise value of $12.36 billion as of Nov 19, 2026, 13:51 WIB. The stock price on Pluang is USD 64.50, up 1.38% for the day, with strong buying interest reflected in a 95% buy order activity. Typical investors on Pluang hold the stock for about 25 days, indicating a moderately active trading pattern.

More News (TEM)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App